白蛋白结合型紫杉醇联合抑癌散结汤治疗胰腺癌的临床疗效

摘要

Objective:To explore the clinical efficacy of albumin bound paclitaxel combined with Yiai Sanjie Decoction in the treatment of pancreatic cancer.Methods:A total of 66 cases of pancreatic cancer patients in our hospital from April 2013 to June 2017 were selected and divided randomly into control group and study group , with 33 cases in each group.Patients in control group were treated with GEM chemotherapy regimens combined with albumin bound paclitaxel , and patients in study group were treated with Yiai Sanjie Decoction on the basis of control group.6 months after continuous treatment , the clinical efficacy and KPS scores in 2 groups were statisticsed; the serum tumor marks molecules before and after treatment in 2 groups were detected and compared ;the occurrence of adverse reaction in 2 groups were compared during treatment.Results:The RR in study group 6 months after treatment was 75.76%, which was higher than that 51.52%in control group (P＜0.05); the KPS score effective rate in study group 6 months after treatment was 87.88%, which was higher than that 66.67%in control group (P＜0.05), and the KPS score in study group 6 months after treatment was also higher than that in control group (P＜0.01); compared with before treatment, the serum CEA, CA125 and CA19－9 levels in 2 groups decreased after treatment , and study group was lower than control group (P＜0.05); compared with control group , the proportion of patients with Ⅰ+Ⅱclass nausea and vomiting, aminotransferase on the high side and thrombocytopenia in study group decreased significantly ( P＜0.05).Conclusion:Albumin bound paclitaxel com－bined with Yiai Sanjie Decoction can reduce the serum tumor markers molecules content of pancreatic cancer patients , enhance the clinical efficacy significantly , and lessen the adverse reaction of chemotherapy , improve the patients'prognosis.%目的:探讨白蛋白结合型紫杉醇联合抑癌散结汤治疗胰腺癌的临床疗效.方法:选取2013年4月至2017年6月郑州大学第二附属医院收治的胰腺癌患者66例,随机分为对照组及观察组,每组33例.对照组患者以GEM化疗方案联合白蛋白结合型紫杉醇治疗,观察组在对照组的基础上联合抑癌散结汤治疗,连续治疗6个月后,统计2组临床疗效及KPS评分;检测并比较治疗前后2组血清肿瘤标志物水平;比较2组患者治疗期间不良反应发生情况.结果:治疗6个月后观察组RR为75.76%,较对照组的51.52%显著升高(P＜0.05);治疗6个月后,观察组患者KPS评分有效率为87.88%,较对照组的66.67%显著升高(P＜0.05);且观察组KPS评分亦显著高于对照组(P＜0.01);与治疗前比较,治疗后2组血清癌胚抗原(CEA)、糖链抗原19－9(CA19－9)、糖链抗原125(CA125)水平均显著降低,且观察组显著低于对照组(P＜0.05);与对照组比较,观察组治疗期间Ⅰ+Ⅱ级恶心呕吐、转氨酶升高及Ⅲ+Ⅳ血小板减少患者比例均显著降低(P＜0.05).结论:白蛋白结合型紫杉醇联合抑癌散结汤可显著降低胰腺癌患者血清肿瘤标志物水平,有效提高患者临床疗效,并减少相关化疗不良反应,改善患者预后.